An Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
An Liu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Sha Chen
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing 100700, China
2 shared publications - Cong Guo
Department of Physics, International Centre of Quantum and Molecular Structures, College of Sciences, Shanghai University, Shanghai, China
1 shared publication - Fei Li
Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital Fourth Military Medical University Xi'an Shaanxi China
1 shared publication - Hui Xiao
Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, No. 32 Renmin South Road, Shiyan, 442000, Hubei, China
1 shared publication - Jingjing Yang
National Engineering Research Center of Marine Facilities Aquaculture, Zhejiang Ocean University, Zhoushan, 316004, China
1 shared publication Jintang Cheng
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
1 shared publication
Latest Publications
- Open Access
- 26 April 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 165 (6) , 772-790
Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives
Chitinase‐3‐like protein 1 (CHI3L1) is a secreted glycoprotein characterized by its ability to regulate multiple biological processes, such as the inflammatory response and gene transcriptional signaling activation. Abnormal CHI3L1 expression has been associated with multiple neurological disorders and serves as a biomarker for the early detection of several neurodegenerative diseases. Aberrant CHI3L1 expression is also reportedly associated with brain tumor migration and metastasis, as well as contributions to immune escape, playing important roles in brain tumor progression. CHI3L1 is synthesized and secreted mainly by reactive astrocytes in the central nervous system. Thus, targeting astrocytic CHI3L1 could be a promising approach for the treatment of neurological diseases, such as traumatic brain injury, ischemic stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and glioma. Based on current knowledge of CHI3L1, we assume that it acts as a molecule mediating several signaling pathways driving the initiation and progression of neurological disorders. This narrative review is the first to introduce the potential roles of astrocytic CHI3L1 in neurological disorders. We also equally explore astrocytic CHI3L1 mRNA expression under physiological and pathological conditions. Inhibiting CHI3L1 and disrupting its interaction with its receptors through multiple mechanisms of action are briefly discussed. These endeavors highlight the pivotal roles of astrocytic CHI3L1 in neurological disorders and could contribute to the development of effective inhibitors based on the strategy of structure‐based drug discovery, which could be an attractive therapeutic approach for neurological disease treatment. image
- 26 April 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 165 (6) , 772-790
Open AccessAstrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives
Chitinase‐3‐like protein 1 (CHI3L1) is a secreted glycoprotein characterized by its ability to regulate multiple biological processes, such as the inflammatory response and gene transcriptional signaling activation. Abnormal CHI3L1 expression has been associated with multiple neurological disorders and serves as a biomarker for the early detection of several neurodegenerative diseases. Aberrant CHI3L1 expression is also reportedly associated with brain tumor migration and metastasis, as well as contributions to immune escape, playing important roles in brain tumor progression. CHI3L1 is synthesized and secreted mainly by reactive astrocytes in the central nervous system. Thus, targeting astrocytic CHI3L1 could be a promising approach for the treatment of neurological diseases, such as traumatic brain injury, ischemic stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and glioma. Based on current knowledge of CHI3L1, we assume that it acts as a molecule mediating several signaling pathways driving the initiation and progression of neurological disorders. This narrative review is the first to introduce the potential roles of astrocytic CHI3L1 in neurological disorders. We also equally explore astrocytic CHI3L1 mRNA expression under physiological and pathological conditions. Inhibiting CHI3L1 and disrupting its interaction with its receptors through multiple mechanisms of action are briefly discussed. These endeavors highlight the pivotal roles of astrocytic CHI3L1 in neurological disorders and could contribute to the development of effective inhibitors based on the strategy of structure‐based drug discovery, which could be an attractive therapeutic approach for neurological disease treatment. image
- 28 July 2020
- Published by Wiley in Biomedical Chromatography
- Vol. 34 (12) , e4958
Quantification of 10 bioactive components of Yazhangsan in rat plasma by LC–MS/MS and its application
Yazhangsan (YZS) is a common prescription for the treatment of cough and asthma caused by wind‐cold. The purpose of this study was to investigate the pharmacokinetic profiles of 10 bioactive components in YZS. A simple, sensitive and reliable high‐performance liquid chromatography coupled with a triple‐quadruple mass spectrometry method (LC–MS/MS) was developed and fully validated in this study for the measurement of these 10 bioactive compounds in rat plasma. One‐step protein precipitation method using methanol was applied to the treatment of rat plasma samples. Chromatographic separation was conducted on a C18 column by gradient elution, and water (containing 0.1% formic acid) and acetonitrile were chosen as the mobile phase. The analytes were quantified by using a mass spectrometer in multiple reaction monitoring scanning mode, and electrospray ionization was performed in positive and negative ion modes. The established method met the requirements for the quantification of these 10 bioactive compounds in biological samples, and it was successfully applied to the pharmacokinetic study of 10 components in rats after the intragastrical administration of YZS. This study will lay a foundation for the investigation of the mechanism of action of YZS and provide useful data for the rational use of YZS in clinical.
- 28 July 2020
- Published by Wiley in Biomedical Chromatography
- Vol. 34 (12) , e4958
Quantification of 10 bioactive components of Yazhangsan in rat plasma by LC–MS/MS and its application
Yazhangsan (YZS) is a common prescription for the treatment of cough and asthma caused by wind‐cold. The purpose of this study was to investigate the pharmacokinetic profiles of 10 bioactive components in YZS. A simple, sensitive and reliable high‐performance liquid chromatography coupled with a triple‐quadruple mass spectrometry method (LC–MS/MS) was developed and fully validated in this study for the measurement of these 10 bioactive compounds in rat plasma. One‐step protein precipitation method using methanol was applied to the treatment of rat plasma samples. Chromatographic separation was conducted on a C18 column by gradient elution, and water (containing 0.1% formic acid) and acetonitrile were chosen as the mobile phase. The analytes were quantified by using a mass spectrometer in multiple reaction monitoring scanning mode, and electrospray ionization was performed in positive and negative ion modes. The established method met the requirements for the quantification of these 10 bioactive compounds in biological samples, and it was successfully applied to the pharmacokinetic study of 10 components in rats after the intragastrical administration of YZS. This study will lay a foundation for the investigation of the mechanism of action of YZS and provide useful data for the rational use of YZS in clinical.
- 1 September 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (17) , 4061-4065
Design, synthesis and evaluation of 2,2-dimethyl-1,3-dioxolane derivatives as human rhinovirus 3C protease inhibitors
- 1 September 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (17) , 4061-4065
Design, synthesis and evaluation of 2,2-dimethyl-1,3-dioxolane derivatives as human rhinovirus 3C protease inhibitors
- 1 January 2017
- Published by Elsevier in Fitoterapia
- Vol. 116, 17-23
New phenylpropanoid-substituted flavan-3-ols and flavonols from the leaves of Uncaria rhynchophylla
- 1 January 2017
- Published by Elsevier in Fitoterapia
- Vol. 116, 17-23
New phenylpropanoid-substituted flavan-3-ols and flavonols from the leaves of Uncaria rhynchophylla